Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

• Status: Completed
• Trial end date: 2021-04-08

Summary

This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

• Phase: Phase 3

Details

• Lead Sponsor: Amgen
• Treatments: Antibodies; Antibodies, Bispecific; Blinatumomab